By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Integrative Cancer Therapies (2019)
0
0
Seminars in Cancer Biology (2018): 85-102
0
0
Load More
Kulvinder Singh Saini
Department of Biotechnology
Ranbaxy Research Laboratories
Follow
Claim
分享
Follow
Claim
分享
基本信息
views: 51
Career TrajectoryBio
President and CSO at NGP (https://nextgenpharma.com.au). Previously, Professor of Biotech & Genomics at www.kau.edu.sa
(2013-2018). From 2010-2012, he was Director-R&D at Eternal University (https://www.eternaluniversity.edu.in). Earlier, he was Director of Biotech and Bioinfo at Ranbaxy, India & Assoc. Director-Oncology at AlphaGene, Boston. PhD-Animal Biochem from Sydney University, Australia. Postdoc-Case Western Med School, Cleveland, USA. Research Fellow-Harvard Med School, Boston, USA.
Research Interests
Author Statistics
#Papers: 86
#Citation: 2301
H-Index: 24
G-Index: 47
Sociability: 7
Diversity: 3
Activity: 2
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn